Apollomics, Inc. (NASDAQ:APLMW – Get Free Report) was the target of a significant increase in short interest in July. As of July 31st, there was short interest totaling 43,253 shares, an increase of 64.2% from the July 15th total of 26,338 shares. Based on an average daily volume of 32,613 shares, the days-to-cover ratio is currently 1.3 days.
Apollomics Price Performance
APLMW stock remained flat at $0.02 during mid-day trading on Monday. The company’s stock had a trading volume of 400 shares, compared to its average volume of 62,732. Apollomics has a 12-month low of $0.00 and a 12-month high of $0.23. The stock’s 50 day moving average is $0.02 and its 200 day moving average is $0.01.
Apollomics Company Profile
Apollomics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and potential commercialization of novel oncology therapies. Since its founding, the company has concentrated on creating targeted and immuno-oncology candidates designed to address unmet needs in solid tumors. Apollomics maintains headquarters in the United States with key research operations in China, leveraging a dual-site strategy to accelerate global development timelines.
The company’s pipeline encompasses a range of therapeutic modalities, including monoclonal antibodies, antibody-drug conjugates and bispecific constructs.
Featured Stories
- Five stocks we like better than Apollomics
- Birkenstock Beats the Skeptics—But Not on EPS
- D-Wave Has Momentum—What Does It Need to Keep It Going?
- TSMC’s Insider Buying Wave Comes With a Bigger AI Question for Investors
- Looking Beyond CrowdStrike? 3 AI Security Stocks Stand Out
Receive News & Ratings for Apollomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollomics and related companies with MarketBeat.com's FREE daily email newsletter.
